Prosecution Insights
Last updated: April 19, 2026
Application No. 18/210,213

METHODS OF DETECTING SIGNATURES OF DISEASE OR CONDITIONS IN BODILY FLUIDS

Non-Final OA §101§DP
Filed
Jun 15, 2023
Examiner
SWITZER, JULIET CAROLINE
Art Unit
1682
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
President and Fellows of Harvard College
OA Round
2 (Non-Final)
42%
Grant Probability
Moderate
2-3
OA Rounds
3y 10m
To Grant
95%
With Interview

Examiner Intelligence

Grants 42% of resolved cases
42%
Career Allow Rate
207 granted / 496 resolved
-18.3% vs TC avg
Strong +53% interview lift
Without
With
+53.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 10m
Avg Prosecution
48 currently pending
Career history
544
Total Applications
across all art units

Statute-Specific Performance

§101
18.7%
-21.3% vs TC avg
§103
23.4%
-16.6% vs TC avg
§102
17.9%
-22.1% vs TC avg
§112
29.1%
-10.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 496 resolved cases

Office Action

§101 §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application is being examined under the pre-AIA first to invent provisions. Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 10/15/25 has been entered. Applicant’s arguments, see pages 6-7, filed 10/15/25, with respect to the rejection(s) of the claim(s) under 102, 103, and double patenting have been fully considered and are persuasive. Therefore, the rejection has been withdrawn. However, upon further consideration, a new ground(s) of rejection is made to address the amended claims. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 1-13 are rejected under 35 U.S.C. 101 because the claimed invention is directed to an abstract idea without significantly more. The claim(s) recite(s) “detecting a significant difference” in the profiles which is a mental process that occurs by comparing the two previously obtained profiles. This judicial exception is not integrated into a practical application because the claims do not apply or use the judicial exception in any way. The claim(s) does/do not include additional elements that are sufficient to amount to significantly more than the judicial exception because the steps in addition to the judicial exception are mere data gathering steps set forth at an extremely high level of generality. In addition to the judicial exceptions some claims recite steps of isolating the relevant cells by FACS or by using antibodies, measuring expression profiles of the markers from hematopoietic phagocytic and non-phagocytic cells from an individual having cancer. These steps are pre-solution data gathering activities recited at an extremely high level of generality that are essential to gathering the data necessary for the practice of the “detecting” step. These step employs well-established routine and conventional techniques, which were known at the time the invention was made. See for example, Palmer et al. and Tang et al. who both exemplify methods where hematopoietic cells are sorted by FACS or the use of antibodies and then expression is measured by cell type. Taken together, these represent a state of the prior art where the basic techniques were routinely practiced. Furthermore, the specification teaches many methods for obtaining expression profiles that were well known in the art, see pages 28-34. The specification also teaches isolating desired cell types by FACS or by using antibodies were both well known (specification p. 5-6, 9). Furthermore, these steps are recited at such a high level of generality, they merely instruct a scientist to use any detection technique for any possible type of marker to obtain the necessary information for implementing the judicial exceptions. When recited at this high level of generality, there is no meaningful limitation, such as a particular or unconventional machine or a transformation of a particular article, in this step that distinguishes it from well-understood, routine, and conventional data gathering activity engaged in by scientists prior to applicant’s invention, and at the time the application was filed, e.g., the routine and conventional techniques of detecting a protein using an antibody to that protein. Further, it is well established that the mere physical or tangible nature of additional elements such as the obtaining and detecting steps does not automatically confer eligibility on a claim directed to an abstract idea (see, e.g., Alice Corp. v. CLS Bank Int’l, 134 S.Ct. 2347, 2358-59 (2014)). Consideration of the additional elements as a combination also adds no other meaningful limitations to the exception not already present when the elements are considered separately. Unlike the eligible claim in Diehr in which the elements limiting the exception are individually conventional, but taken together act in concert to improve a technical field, the claim here does not invoke any of the considerations that courts have identified as providing significantly more than an exception. Even when viewed as a combination, the additional elements fail to transform the exception into a patent-eligible application of that exception as the combination of steps in addition to the judicial exception was routine and conventional. Thus, the claim as a whole does not amount to significantly more than the exception itself. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Juliet Switzer whose telephone number is (571)272-0753. The examiner can normally be reached Monday to Thursday, 8:00 AM-3:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Winston Shen can be reached at (571)-272-3157. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Juliet Switzer Primary Examiner Art Unit 1682 /JULIET C SWITZER/Primary Examiner, Art Unit 1682
Read full office action

Prosecution Timeline

Jun 15, 2023
Application Filed
Dec 14, 2024
Final Rejection — §101, §DP
Jun 23, 2025
Notice of Allowance
Oct 15, 2025
Request for Continued Examination
Oct 16, 2025
Response after Non-Final Action
Oct 27, 2025
Non-Final Rejection — §101, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12584181
Detection of Mycobacterium species
2y 5m to grant Granted Mar 24, 2026
Patent 12559789
A METHOD OF TARGETING PATIENT-SPECIFIC ONCOGENES IN EXTRACHROMOSOMAL DNA TO TREAT GLIOBLASTOMA
2y 5m to grant Granted Feb 24, 2026
Patent 12559804
LOOP-MEDIATED ISOTHERMAL AMPLIFICATION PRIMERS FOR VIBRIO PARAHAEMOLYTICUS DETECTION AND USES THEREOF
2y 5m to grant Granted Feb 24, 2026
Patent 12545954
MULTIPLEXED ASSAY FOR QUANTITATING AND ASSESSING INTEGRITY OF CELL-FREE DNA IN BIOLOGICAL FLUIDS FOR CANCER DIAGNOSIS, PROGNOSIS AND SURVEILLANCE
2y 5m to grant Granted Feb 10, 2026
Patent 12522873
NOVEL ALK AND NTRK1 FUSION MOLECULES AND USES THEREOF
2y 5m to grant Granted Jan 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

2-3
Expected OA Rounds
42%
Grant Probability
95%
With Interview (+53.0%)
3y 10m
Median Time to Grant
Moderate
PTA Risk
Based on 496 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month